MktsMarkets

Corvus Pharmaceuticals, Inc.
NASDAQ: CRVSKey statistics
CRVS News
Stories mentioning CRVS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 11,175 | 9,939 | 8,454 | 7,873 | 7,453 | 5,974 | 5,222 | 4,114 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 14,877 | 12,217 | 10,572 | 10,260 | 9,922 | 8,105 | 7,255 | 5,935 |
| Operating Income (Loss) | (14,877) | (12,217) | (10,572) | (10,260) | (9,922) | (8,105) | (7,255) | (5,935) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | ||||||
| Net Income (Loss) | (13,692) | (12,321) | (10,157) | (7,998) | 15,193 | (12,113) | (40,217) | (4,262) |
| Earnings Per Share (Basic) | (0.15) | (0.16) | (0.12) | (0.10) | 0.21 | (0.20) | (0.60) | (0.07) |
| Earnings Per Share (Diluted) | (0.15) | (0.15) | (0.12) | (0.10) | (0.13) | (0.20) | (0.60) | (0.07) |
| Weighted Average Shares Outstanding (Basic) | 89,997 | 78,965 | 82,836 | 77,774 | 72,126 | 60,985 | 66,701 | 59,710 |
| Weighted Average Shares Outstanding (Diluted) | 89,997 | 79,743 | 82,836 | 77,774 | 75,153 | 60,985 | 66,701 | 59,710 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CRVS
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a stock listed on the Nasdaq Stock Market under the ticker symbol CRVS. It last traded at $9.67 (Nov 20, 2026, 4:00 PM ET), down 3.4% on the day. That gives Corvus Pharmaceuticals a market capitalisation of $853.7M.
Over the past 52 weeks CRVS has traded between $6.39 and $26.95.
For the quarter ended Mar 31, 2026 it reported a net loss of $13.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$13.7M |
| Dec 31, 2025 | — | -$12.3M |
| Sep 30, 2025 | — | -$10.2M |
| Jun 30, 2025 | — | -$8.0M |
From Corvus Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…